Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 753

1.

The role of individual susceptibility in cancer burden related to environmental exposure.

Bartsch H, Hietanen E.

Environ Health Perspect. 1996 May;104 Suppl 3:569-77. Review.

2.

Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo.

Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG.

J Natl Cancer Inst. 1995 Jun 21;87(12):902-7. Erratum in: J Natl Cancer Inst 1996 Nov 6;88(21):1595.

PMID:
7666479
3.

Molecular epidemiology in cancer research.

Collins AR.

Mol Aspects Med. 1998 Dec;19(6):359-432. Review.

PMID:
10385877
4.

Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.

Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K.

Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28. Review.

5.

Environmental and chemical carcinogenesis.

Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA.

Semin Cancer Biol. 2004 Dec;14(6):473-86. Review.

PMID:
15489140
6.

Genetic polymorphisms and lung cancer susceptibility: a review.

Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM.

Lung Cancer. 2002 Sep;37(3):241-56. Review.

PMID:
12234692
7.
8.

Interaction between dose and susceptibility to environmental cancer: a short review.

Hietanen E, Husgafvel-Pursiainen K, Vainio H.

Environ Health Perspect. 1997 Jun;105 Suppl 4:749-54. Review.

9.

Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.

Badawi AF, Stern SJ, Lang NP, Kadlubar FF.

Prog Clin Biol Res. 1996;395:109-40. Review.

PMID:
8895986
10.

Cancer and phase II drug-metabolizing enzymes.

Sheweita SA, Tilmisany AK.

Curr Drug Metab. 2003 Feb;4(1):45-58. Review.

PMID:
12570745
11.

Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.

Thier R, BrĂ¼ning T, Roos PH, Rihs HP, Golka K, Ko Y, Bolt HM.

Int J Hyg Environ Health. 2003 Jun;206(3):149-71. Review.

PMID:
12872524
12.

Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.

Gao WM, Romkes M, Day RD, Siegfried JM, Luketich JD, Mady HH, Melhem MF, Keohavong P.

Carcinogenesis. 2003 Oct;24(10):1671-6. Epub 2003 Jul 4.

PMID:
12844488
13.

Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.

Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M.

Cancer Res. 1996 Jan 1;56(1):72-6.

14.

Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma.

Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, Guernsey DL, McLaughlin J.

Cancer Detect Prev. 2003;27(2):139-46.

PMID:
12670526
15.

Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose.

Kawajiri K, Nakachi K, Imai K, Hayashi S, Watanabe J.

Princess Takamatsu Symp. 1990;21:55-61.

PMID:
2134690
16.

Combined genetic polymorphism and risk for development of lung cancer.

el-Zein R, Zwischenberger JB, Wood TG, Abdel-Rahman SZ, Brekelbaum C, Au WW.

Mutat Res. 1997 Nov 28;381(2):189-200.

PMID:
9434875
17.

[Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].

Pavanello S, Clonfero E.

G Ital Med Lav Ergon. 2004 Oct-Dec;26(4):311-21. Review. Italian.

PMID:
15584438
18.

Significance of genetic polymorphisms in glutathione S-transferase multigene family and lung cancer risk.

Reszka E, Wasowicz W.

Int J Occup Med Environ Health. 2001;14(2):99-113. Review.

PMID:
11548073
19.

Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans.

Bartsch H, Rojas M, Alexandrov K, Camus AM, Castegnaro M, Malaveille C, Anttila S, Hirvonen K, Husgafvel-Pursiainen K, Hietanen E, et al.

Pharmacogenetics. 1995;5 Spec No:S84-90.

PMID:
7581496
20.

Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.

Wang X, Christiani DC, Mark EJ, Nelson H, Wiencke JK, Gunn L, Wain JC, Kelsey KT.

Cancer. 1999 Apr 15;85(8):1734-9.

PMID:
10223567

Supplemental Content

Support Center